From identifying the right distributors and KOLs to developing market entry, pricing, and commercialization strategies, we help healthcare companies accelerate successful launches.
We help MedTech companies build the right global distribution strategy by identifying and engaging the right distributors for any market. Sora Lifesciences executes this as a consulting project focused on identifying, assessing, and connecting you with qualified distributors and strategic partners — shortlisting distributors that not only provide broad market coverage but also demonstrate a strong fit with your product positioning and long-term growth objectives. It runs in two phases.
The objective of this phase is to act as your representative and bridge the gap between a shortlist and a signed contract. We handle the heavy lifting of cold outreach and initial vetting so your team only spends time on high-probability meetings.
Which distributors can actually sell this product in this market — and how do we get them to the table?
Tell us what you're launching and which markets you're targeting. We'll come back to you with how a shortlist would be built for your product.
A precision-driven service that meticulously profiles Key Opinion Leaders across 20+ parameters. KOLs act as influencers on physicians' prescribing decisions and the early adoption of brands; they surface the on-the-ground challenges physicians face in managing patient care, their expectations on benefit/safety profile, unmet needs, and the shortcomings of current treatments. Their views serve as an expert informational resource that MedTech companies draw on when framing promotional and brand strategy or during device development — and because their opinions carry immense trust among peer groups, identifying the right ones helps healthcare companies build credibility and the right connection with physicians.
For any given therapy area within a defined geography, we start by identifying a broad list of potential KOLs — identifying the sources, screening the databases, and collecting data across five key areas:
Profiling and ranking then runs in three steps:
Profiling and ranking is scored against a framework agreed with you before the search begins.
Identify and rank potential KOLs based on (but not limited to):
Who are the opinion leaders shaping adoption in this therapy area — and which of them should we engage first?
Entering a new market often requires local representation, registration support, or an in-country partner. Sora Lifesciences helps MedTech companies understand local requirements, identify suitable representation or registration partners, and navigate the early steps toward market access.
Our role is to bridge the gap between regulatory understanding and local execution. Depending on the market and product category, this may include mapping local registration pathways, identifying authorized representatives or registration holders, assessing distributor-led registration options, supporting documentation readiness, and helping you evaluate the commercial and control implications of different representation models. The objective is to enter new markets with a clearer regulatory pathway, suitable local support, and reduced dependency on unverified partners.
Bridging regulatory understanding and local execution for your target market and product category.
The routes to a compliant in-market presence, weighed for cost, control, and speed.
Do we need a local representative to sell here — and if so, which model gives us the best balance of speed, cost and control?
Entering a new market often requires alignment with regulators, payors, reimbursement bodies, hospital decision-makers, and professional associations. Sora Lifesciences helps MedTech companies identify the right stakeholders, understand local decision pathways, and facilitate engagement to reduce uncertainty around market access and commercialization.
Our role is to help you move from high-level market interest to practical stakeholder alignment. Depending on the market and product category, this may include identifying relevant authorities or payor bodies, clarifying documentation expectations, understanding reimbursement or access decision pathways, coordinating expert discussions, and preparing the right value narrative for local stakeholders. The objective is a clearer, more coordinated path to market access and adoption.
The bodies and decision-makers that shape access, reimbursement, and adoption in-market.
Preparing you for structured, credible interactions that reduce market-entry uncertainty.
Which local bodies actually decide whether this product gets used — and how do we get in front of them?
Pricing is one of the most important commercial decisions for any MedTech company preparing for market entry, launch, or international expansion. The right pricing strategy must balance clinical value, competitive positioning, reimbursement realities, hospital procurement expectations, distributor margins, and customer willingness to pay. We help MedTech innovators move beyond cost-plus or competitor-led pricing to develop evidence-based pricing strategies that support adoption, profitability, and sustainable growth — combining desk research, stakeholder interviews, physician or hospital surveys, and pricing analytics across five integrated workstreams.
What price can the market accept, justify, and sustain?
Regulatory clearance and clinical evidence are only the starting point. We help MedTech companies convert launch readiness into market adoption through practical GTM execution — prioritizing target accounts, mapping decision-makers, planning stakeholder engagement, sequencing launch activities, and defining the commercial actions needed to drive early adoption, scale uptake, and build sustainable revenue growth.
If you don’t know, or aren’t sure and want to validate, we can help with a robust, time-tested methodology driven by desk research, stakeholder interviews, and customer feedback surveys. Based on these insights, we develop a practical go-to-market execution roadmap:
The result is a practical launch plan that aligns stakeholders, accelerates adoption, reduces commercialization risk, and converts strategy into sustainable revenue growth.
Who should we target, how should we engage them, and how do we scale adoption?
Built an evidence-based market entry strategy for an advanced wound-management solution entering Sweden — sizing the opportunity, mapping regulatory and reimbursement requirements, and identifying the KOLs and distributors needed to launch.
A Japanese medical device manufacturer engaged us to identify and profile qualified distribution partners for its physiotherapy and rehabilitation devices in Australia, as Step 1 of our distributor matchmaking programme.
A Japanese biopharmaceutical manufacturer engaged us to identify, profile, and approach distribution partners for its injectable joint-care product in Germany, covering Steps 1 and 2 of our distributor matchmaking programme.
Tell us the decision you're facing and we'll scope an evidence-based approach.
Evidence-led market intelligence, commercialization & clinical evidence for MedTech and BioTech.
contactus@soralifesciences.com© 2026 Sora Life Sciences. All rights reserved.